Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC


1 hr



# of Credits



Certificate of Completion

Expiry Date


Immune checkpoint inhibition is the new backbone of first-line treatment in advanced clear cell RCC. This program, endorsed by the Clinical Oncology Society of Australia (COSA), focusses on the outcomes of the Checkmate 214 trial of nivolumab plus ipilimumab in untreated advanced RCC, and its recent 42 month follow-up. A useful refresher on checkpoint inhibition in cancer sets the scene, and the program also features case studies and expert videos exploring RCC prognostication, treatment selection and managing the adverse effects of checkpoint inhibitor immunotherapy.



Dr Laurence Krieger
Consultant Medical Oncologist and General Physicians,
St Leonards, NSW, Australia

Dr Carole Harris
Medical Oncologist,
Kogarah, NSW, Australia

On completion of this program, participants will be better able to:

  • Describe the evolving treatment landscape for clear cell advanced renal cell carcinoma (RCC)
  • Evaluate the role of prognostic classification tools including IMDC and MSKCC risk classification tools
  • Describe the latest clinical data supporting the role of combination immunotherapy in the first-line treatment of patients with Stage IV intermediate-to-poor risk RCC
  • Identify patients with Stage IV RCC who may benefit from first-line combination immunotherapy
  • Feel confident in the early recognition and management of immune-related adverse events in patients treated with immunotherapy

Related Courses